Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamza Hashmi

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
BMJ Quality & Safety|May 8, 2016
Opportunities to improve clinical summaries for patients at hospital dischargeErin Sarzynski, Hamza Hashmi, Jeevarathna Subramanian, et al.
The American Journal of Case Reports|June 6, 2015
Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature ReviewK C Birendra, Muhammad Zubair Afzal, Katherine A Wentland, et al.
Kidney360|February 27, 2026
Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective AnalysisBenjamin Teruel, Ashley L Golbus, Elaine Park, et al.
Cancers|June 10, 2023
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed TherapyShebli Atrash, Aytaj Mammadzadeh, Fulei Peng, et al.
Cureus|March 20, 2020
Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution ExperienceHamza Hashmi, Shruti Bhandari, Jugraj Dhanoa, et al.
Ejhaem|August 19, 2024
<i>"Fast but not so furious"</i>: A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myelomaKevin C Graf, James A Davis, Alyssa Cendagorta, et al.
Transplantation and Cellular Therapy|May 24, 2023
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell TherapyJames A Davis, Douglas W Sborov, William Wesson, et al.
Journal of Hematology|March 10, 2023
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and DexamethasoneOmar Alkharabsheh, Polina Bellman, Zahra Mahmoudjafari, et al.
European Journal of Haematology|August 27, 2024
Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosisUtkarsh Goel, Danai Dima, James Davis, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 25, 2023
Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacyKelly J Gaffney, James A Davis, Mary McGann, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
BMJ Quality & Safety|May 8, 2016
Opportunities to improve clinical summaries for patients at hospital dischargeErin Sarzynski, Hamza Hashmi, Jeevarathna Subramanian, et al.
The American Journal of Case Reports|June 6, 2015
Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature ReviewK C Birendra, Muhammad Zubair Afzal, Katherine A Wentland, et al.
Kidney360|February 27, 2026
Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective AnalysisBenjamin Teruel, Ashley L Golbus, Elaine Park, et al.
Cancers|June 10, 2023
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed TherapyShebli Atrash, Aytaj Mammadzadeh, Fulei Peng, et al.
Cureus|March 20, 2020
Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution ExperienceHamza Hashmi, Shruti Bhandari, Jugraj Dhanoa, et al.
Ejhaem|August 19, 2024
<i>"Fast but not so furious"</i>: A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myelomaKevin C Graf, James A Davis, Alyssa Cendagorta, et al.
Transplantation and Cellular Therapy|May 24, 2023
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell TherapyJames A Davis, Douglas W Sborov, William Wesson, et al.
Journal of Hematology|March 10, 2023
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and DexamethasoneOmar Alkharabsheh, Polina Bellman, Zahra Mahmoudjafari, et al.
European Journal of Haematology|August 27, 2024
Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosisUtkarsh Goel, Danai Dima, James Davis, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 25, 2023
Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacyKelly J Gaffney, James A Davis, Mary McGann, et al.
Pageof 10